Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 215, Issue 1-2, Pages 125-128Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2009.08.007
Keywords
Multiple sclerosis; IFN-beta-1a; Foxp3 expression; CD56(bright) NK cells
Categories
Funding
- Biogen-Idec
- Nancy Davis MS Center Without Walls
- Department of Veterans Affairs Department of Biomedical Research
Ask authors/readers for more resources
Disease modifying effects of interferon (IFN)-beta therapy in patients with multiple sclerosis (MS) may be mediated in part through enhanced immunoregulation by the CD56(bright) subpopulation of natural killer (NK) cells and by Foxp3+ (not italicized) CD4+CD25+ regulatory T cells (Treg). We found that IFN-beta-1a(IM) treatment of relapsing-remitting (RR)MS subjects over 12 months significantly increased both percentage of CD56 (bright) NK cells and Foxp3 mRNA expression compared to baseline values, untreated RRMS subjects and healthy controls (HC). This striking enhancement of two prominent immunoregulatory, pathways lends support to the idea that beneficial effects of IFN-beta-1a in MS include control of pernicious autoimmunity. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available